Joppi, R. and Wild, C. (2012): Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma. DSD: Horizon Scanning in Oncology 23.

Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.

Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.

Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.